ebv lymphoma

Peptide Clinical Trial: How a Synthetic LMP-1 Peptide Revealed EBV Lymphoma Mechanisms

A peptide clinical trial using a synthetic LMP-1 peptide helped researchers at the Medical University of Vienna decode how Epstein-Barr virus (EBV) drives Hodgkin's and non-Hodgkin's lymphomas. The study, published in Frontiers in Immunology, showed that a specific high-affinity LMP-1 peptide variant triggers immune escape via HLA-E signaling, inhibiting natural killer (NK) cells. This article breaks down the findings, explains the role of synthetic peptides in research, and points to Volta Peptides resources for verifying peptide quality.